Close Menu

Diagnostics

News and analysis on diagnostic technologies and applications.

The Australian firm will use the proceeds for R&D, expansion in China, and to fund the development of polygenic risk tests with TGen in the US.

The firm said that it may use some of the net proceeds to acquire or invest in complementary businesses and technologies.

The firm noted that its study showed strong performance data, including high sensitivity and high specificity, in providing results direct from blood.

The researchers said such a screening approach could capture younger individuals who don't regularly visit medical professionals.

The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.

Jun
17

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.